Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

HSV alkaline nuclease as a target for antiviral therapy

Award Number: R21AI195412
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/20/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

HSV alkaline nuclease as a target for antiviral therapy - ABSTRACT Genital herpes, a lifelong sexually transmitted infection caused by either Herpes Simplex Virus 1 or 2 (HSV1/2), is one of the most common STDs in the US with (846 million people infected worldwide). HSV1/2 can cause oral and genital lesions and establish lifelong latent infections which can undergo periodic reactivation. Reactivation can cause painful ulcers and blisters; however, many reactivations are asymptomatic, causing an increased risk of partner transmission. HSV reactivation is particularly problematic in immunocompromised patients and can lead to disseminated life-threatening infections. HSV can also be transmitted to newborns either during or after birth, potentially leading to serious neurological disorders. The severity of this public health epidemic is intensified by the lack of protective vaccines and the inability to cure infections with existing antiviral therapies. Furthermore, it is now recognized that HSV infection can increase the risk of HIV infection. Existing therapies have focused on the HSV DNA polymerase as a target, and most HSV polymerase inhibitors are nucleoside/tides, which are often associated with drug resistance, narrow spectrum and dose-limiting toxicities. New agents with different modes of action are needed not only for the treatment of resistant viruses but also for use in combination therapy to reduce dose-limiting toxicities. New therapies used prophylactically would prevent pathological sequelae of reactivation, as well as viral shedding and transmission to new hosts. We have identified the HSV alkaline nuclease (AN) as a promising and novel HSV target for anti-herpesvirus drug discovery efforts. HSV1 and HSV2 AN are encoded by the UL12 gene, which is highly conserved between HSV1 and 2. We have had a long- standing interest in understanding the role of AN in viral replication primarily relying on genetic methods. A null mutant in AN and a point mutation in the nuclease active site (D340E) are unable to produce infectious virus in cell culture. AN is a member of a large class of two-metal ion-dependent (TMID) enzymes, whose active sites coordinate divalent cations essential for catalysis. Many viruses utilize TMID enzymes for processing and manipulation of viral nucleic acids. The successful development of selective and safe inhibitors of two viral TMID enzymes (HIV integrase and influenza endonuclease, PA) shows that it is possible to block TMID nuclease activity by metal-coordinating enzyme inhibitors. We have shown that the HSV alkaline nuclease is essential for productive HSV infection as nuclease dead HSV mutants are defective in viral spread and virus production. Furthermore, we have identified several lead compounds that block AN activity and produce strong antiviral responses in cell culture and animal models. In this proposal we will continue our efforts to develop antiviral agents that inhibit HSV1/2 alkaline nuclease, UL12.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $263,375 )
2026	2026	UNIVERSITY OF CONNECTICUT HEALTH CENTER	263 FARMINGTON AVE	FARMINGTON	CT	06030	CAPITOL	USA	Allergy and Infectious Diseases Research	000	1	4/21/2026	NEW	$263,375
														Subtotal = $263,375

Grand Total All Awards = $263,375

Top

All Categories

About

Search

Reports

Data Submission

Award Information

HSV alkaline nuclease as a target for antiviral therapy

Award Number: R21AI195412

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/20/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer